Pfizer has announced it has formally requested emergency use authorisation for its Covid-19 vaccine in children aged five to eleven.
Children have become increasingly infected by the Delta variant across the world, relative to other variants.
The majority of children who become infected only suffer mild illness, or are assymptomatic.
In September, Pfizer began submitting data to the Food and Drug Administration (FDA) in the United States.
Pfizer tweeted today: “We and BioNTech officially submitted our request to USFDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12.”
“We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat,” Pfizer said.
The FDA has scheduled a meeting of of an advisory committee to review the data on 26th October, before making a decision.
IMAGE – Army Spc. Angel Laureano holds a vial of the COVID-19 vaccine, Walter Reed National Military Medical Center, Bethesda, Md., Dec. 14, 2020. (DoD photo by Lisa Ferdinando)